132 related articles for article (PubMed ID: 28696155)
1. Studies of the precipitation pattern of paclitaxel in intravenous infusions and rat plasma using laser nephelometry.
El Nemr S; Al-Najjar BY; Omer HK; Elhissi AMA; Alhnan MA
Pharm Dev Technol; 2018 Jan; 23(1):67-75. PubMed ID: 28696155
[TBL] [Abstract][Full Text] [Related]
2. Novel biocompatible intraperitoneal drug delivery system increases tolerability and therapeutic efficacy of paclitaxel in a human ovarian cancer xenograft model.
Vassileva V; Grant J; De Souza R; Allen C; Piquette-Miller M
Cancer Chemother Pharmacol; 2007 Nov; 60(6):907-14. PubMed ID: 17375303
[TBL] [Abstract][Full Text] [Related]
3. Ionic-Liquid-Based Paclitaxel Preparation: A New Potential Formulation for Cancer Treatment.
Chowdhury MR; Moshikur RM; Wakabayashi R; Tahara Y; Kamiya N; Moniruzzaman M; Goto M
Mol Pharm; 2018 Jun; 15(6):2484-2488. PubMed ID: 29762034
[TBL] [Abstract][Full Text] [Related]
4. Systemic toxicity induced by paclitaxel in vivo is associated with the solvent cremophor EL through oxidative stress-driven mechanisms.
Campos FC; Victorino VJ; Martins-Pinge MC; Cecchini AL; Panis C; Cecchini R
Food Chem Toxicol; 2014 Jun; 68():78-86. PubMed ID: 24657178
[TBL] [Abstract][Full Text] [Related]
5. Paclitaxel in tyrosine-derived nanospheres as a potential anti-cancer agent: in vivo evaluation of toxicity and efficacy in comparison with paclitaxel in Cremophor.
Sheihet L; Garbuzenko OB; Bushman J; Gounder MK; Minko T; Kohn J
Eur J Pharm Sci; 2012 Feb; 45(3):320-9. PubMed ID: 22155544
[TBL] [Abstract][Full Text] [Related]
6. Pharmacologic sensitivity of paclitaxel to its delivery vehicles drives distinct clinical outcomes of paclitaxel formulations.
Li Y; Chen N; Palmisano M; Zhou S
Mol Pharm; 2015 Apr; 12(4):1308-17. PubMed ID: 25714793
[TBL] [Abstract][Full Text] [Related]
7. Paclitaxel and its formulations.
Singla AK; Garg A; Aggarwal D
Int J Pharm; 2002 Mar; 235(1-2):179-92. PubMed ID: 11879753
[TBL] [Abstract][Full Text] [Related]
8. In vivo biocompatibility, pharmacokinetics, antitumor efficacy, and hypersensitivity evaluation of ionic liquid-mediated paclitaxel formulations.
Chowdhury MR; Moshikur RM; Wakabayashi R; Tahara Y; Kamiya N; Moniruzzaman M; Goto M
Int J Pharm; 2019 Jun; 565():219-226. PubMed ID: 31077761
[TBL] [Abstract][Full Text] [Related]
9. Paclitaxel-loaded PEGylated PLGA-based nanoparticles: in vitro and in vivo evaluation.
Danhier F; Lecouturier N; Vroman B; Jérôme C; Marchand-Brynaert J; Feron O; Préat V
J Control Release; 2009 Jan; 133(1):11-7. PubMed ID: 18950666
[TBL] [Abstract][Full Text] [Related]
10. Liposomal paclitaxel induces fewer hematopoietic and cardiovascular complications than bioequivalent doses of Taxol.
Huang ST; Wang YP; Chen YH; Lin CT; Li WS; Wu HC
Int J Oncol; 2018 Sep; 53(3):1105-1117. PubMed ID: 29956746
[TBL] [Abstract][Full Text] [Related]
11. Inter-relationships of paclitaxel disposition, infusion duration and cremophor EL kinetics in cancer patients.
van Zuylen L; Gianni L; Verweij J; Mross K; Brouwer E; Loos WJ; Sparreboom A
Anticancer Drugs; 2000 Jun; 11(5):331-7. PubMed ID: 10912949
[TBL] [Abstract][Full Text] [Related]
12. Dosing sequence-dependent pharmacokinetic interaction of oxaliplatin with paclitaxel in the rat.
Liu J; Kraut EH; Balcerzak S; Grever M; D'Ambrosio S; Chan KK
Cancer Chemother Pharmacol; 2002 Dec; 50(6):445-53. PubMed ID: 12451470
[TBL] [Abstract][Full Text] [Related]
13. Alternative formulations of paclitaxel.
Terwogt JM; Nuijen B; Huinink WW; Beijnen JH
Cancer Treat Rev; 1997 Mar; 23(2):87-95. PubMed ID: 9225960
[TBL] [Abstract][Full Text] [Related]
14. Novel self-assembling PEG-p-(CL-co-TMC) polymeric micelles as safe and effective delivery system for paclitaxel.
Danhier F; Magotteaux N; Ucakar B; Lecouturier N; Brewster M; Préat V
Eur J Pharm Biopharm; 2009 Oct; 73(2):230-8. PubMed ID: 19577643
[TBL] [Abstract][Full Text] [Related]
15. Paclitaxel in cancer treatment: perspectives and prospects of its delivery challenges.
Singh S; Dash AK
Crit Rev Ther Drug Carrier Syst; 2009; 26(4):333-72. PubMed ID: 20001890
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics, tissue distribution and anti-tumour efficacy of paclitaxel delivered by polyvinylpyrrolidone solid dispersion.
Liu X; Sun J; Chen X; Wang S; Scott H; Zhang X; Zhang Q
J Pharm Pharmacol; 2012 Jun; 64(6):775-82. PubMed ID: 22571255
[TBL] [Abstract][Full Text] [Related]
17. Improved safety and efficacy of a lipid emulsion loaded with a paclitaxel-cholesterol complex for the treatment of breast tumors.
Ye J; Liu Y; Xia X; Meng L; Dong W; Wang R; Fu Z; Liu H; Han R
Oncol Rep; 2016 Jul; 36(1):399-409. PubMed ID: 27175803
[TBL] [Abstract][Full Text] [Related]
18. Thermosensitive and biodegradable polymeric micelles for paclitaxel delivery.
Soga O; van Nostrum CF; Fens M; Rijcken CJ; Schiffelers RM; Storm G; Hennink WE
J Control Release; 2005 Mar; 103(2):341-53. PubMed ID: 15763618
[TBL] [Abstract][Full Text] [Related]
19. Dendritic polyglycerol sulfate as a novel platform for paclitaxel delivery: pitfalls of ester linkage.
Sousa-Herves A; Würfel P; Wegner N; Khandare J; Licha K; Haag R; Welker P; Calderón M
Nanoscale; 2015 Mar; 7(9):3923-32. PubMed ID: 25516353
[TBL] [Abstract][Full Text] [Related]
20. Novel Water-Borne Polyurethane Nanomicelles for Cancer Chemotherapy: Higher Efficiency of Folate Receptors Than TRAIL Receptors in a Cancerous Balb/C Mouse Model.
Ajorlou E; Khosroushahi AY; Yeganeh H
Pharm Res; 2016 Jun; 33(6):1426-39. PubMed ID: 26908046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
